OrganAID, a biotechnology spin-off co-founded by researchers from the Institute of Neurosciences of the University of Barcelona (UBneuro), has been recognized as one of the winners of the ChemoStart IX Edition, a leading international program promoting innovation in health and life sciences
The recognition was announced following ChemoStart’s Pitch Day in Madrid, where twelve finalist startups presented their projects before a panel of experts, investors, and leaders from the biotechnology and pharmaceutical sectors. This year’s edition received more than one hundred international applications, consolidating ChemoStart’s position as a key European benchmark for scientific innovation with high translational potential.
Advancing precision medicine through organoids and artificial intelligence
OrganAID has developed a pioneering biotechnology platform that integrates patient-derived organoids with advanced artificial intelligence tools. This approach enables the personalized prediction of patient responses to pharmacological treatments, accelerating the development of precision medicine strategies and improving decision-making in drug discovery and therapeutic development
Building on years of cutting-edge research in neuroscience and cellular modeling, OrganAID’s technology allows researchers to analyze the efficacy and safety of experimental treatments in a highly precise and patient-specific manner. By leveraging large databases of organoid images and AI-powered predictive systems, the platform can assess neurological toxicity and therapeutic potential, with applications extending beyond neuroscience to oncological and genetic diseases
From academic research to biomedical innovation
OrganAID was created as a spin-off of the University of Barcelona and Pompeu Fabra University, led by UBneuro researcher Prof. Sandra Acosta, with the aim of translating advanced organoid and AI technologies into real-world biomedical solutions. The company represents a significant step towards personalized and predictive medicine, while also contributing to the reduction of animal testing in preclinical research
The recognition by ChemoStart highlights OrganAID’s scientific excellence, clinical translation potential, and capacity to address critical challenges in healthcare, particularly in the fields of oncology and precision medicine.
“We are extremely grateful to ChemoStart program for this prize, and the support it will provide us the program to advance toward implementing personalized medicine in neurological disorders” highlights Prof. Sandra Acosta.
For more information about OrganAID and its technology, visit https://organaid.eu/.
